Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease
Authors:
- Subha Karumuthil-MelethilSKSubha Karumuthil-Melethil
- Sahana Nagabhushan KalburgiSKSahana Nagabhushan Kalburgi
- Patrick ThompsonPTPatrick Thompson
- Michael TropakMTMichael Tropak
- Michael D. KaytorMKMichael D. Kaytor
- John G. KeimelJKJohn G. Keimel
- Brian L. MarkBMBrian L. Mark
- Jagdeep S. WaliaJWJagdeep S. Walia
- Steven James GraySGSteven James Gray
- 19 May 2016
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 27 (7) , 509-521
Abstract
G M2 gangliosidosis is a family of three genetic neurodegenerative disorders caused by the accumulation of G M2 ganglioside (G M2 ) in neuronal tissue. Two of these are due to the deficiency of the heterodimeric (α–β), “A” isoenzyme of lysosomal β-hexosaminidase (HexA). Mutations in the α-subunit (encoded by HEXA ) lead to Tay-Sachs disease (TSD), whereas mutations in the β-subunit (encoded by HEXB ) lead to Sandhoff disease (SD). The third form results from a deficiency of the G M2 activator protein (G M2 AP), a substrate-specific cofactor for HexA. In their infantile, acute forms, these diseases rapidly progress with mental and psychomotor deterioration resulting in death by approximately 4 years of age. After gene transfer that overexpresses one of the deficient subunits, the amount of HexA heterodimer formed would empirically be limited by the availability of the other endogenous Hex subunit. The present study used a new variant of the human HexA α-subunit, μ, incorporating critical sequences from the β-subunit that produce a stable homodimer (HexM) and promote functional interactions with the G M2 AP– G M2 complex. We report the design of a compact adeno-associated viral (AAV) genome using a synthetic promoter–intron combination to allow self-complementary (sc) packaging of the HEXM gene. Also, a previously published capsid mutant, AAV9.47, was used to deliver the gene to brain and spinal cord while having restricted biodistribution to the liver. The novel capsid and cassette design combination was characterized in vivo in TSD mice for its ability to efficiently transduce cells in the central nervous system when delivered intravenously in both adult and neonatal mice. This study demonstrates that the modified HexM is capable of degrading long-standing G M2 storage in mice, and it further demonstrates the potential of this novel scAAV vector design to facilitate widespread distribution of the HEXM gene or potentially other similar-sized genes to the nervous system.Keywords
This publication has 52 references indexed in Scilit:
- Mucopolysaccharidosis-like phenotype in feline Sandhoff disease and partial correction after AAV gene therapyMolecular Genetics and Metabolism, 2015
- Improving Single Injection CSF Delivery of AAV9-mediated Gene Therapy for SMA: A Dose–response Study in Mice and Nonhuman PrimatesMolecular Therapy, 2015
- A large animal model of spinal muscular atrophy and correction of phenotypeAnnals of Neurology, 2014
- Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapyJournal of Clinical Investigation, 2013
- Correction of Pathological Accumulation of Glycosaminoglycans in Central Nervous System and Peripheral Tissues of MPSIIIA Mice Through Systemic AAV9 Gene TransferHuman Gene Therapy, 2012
- Optimizing Promoters for Recombinant Adeno-Associated Virus-Mediated Gene Expression in the Peripheral and Central Nervous System Using Self-Complementary VectorsHuman Gene Therapy, 2011
- Widespread distribution of β-hexosaminidase activity in the brain of a Sandhoff mouse model after coinjection of adenoviral vector and mannitolGene Therapy, 2003
- Adenoviral Gene Therapy of the Tay-Sachs Disease in Hexosaminidase A-Deficient Knock-Out MiceHuman Molecular Genetics, 1999
- Specificity of Mouse GM2 Activator Protein and β-N-Acetylhexosaminidases A and BJournal of Biological Chemistry, 1998
- Dramatically Different Phenotypes in Mouse Models of Human Tay-Sachs and Sandhoff DiseasesHuman Molecular Genetics, 1996